“This year, Phase 2 data from our CRC study evaluating tmAb A in combination with Bevacizumab will be available, which could enable a Phase 3 study in an all comers population.”

In context

“rated approval in the second quarter for Teliso-V as a monotherapy in previously treated non-squamous non-small cell lung cancer with high c-Met expression. This is a segment of lung cancer with high unmet need and when approved, Teliso-V will be the first c-Met directed ADC for these patients. We're also making good progress with tmAb A, our next generation c-Met ADC, a Phase 2 dose optimization study evaluating tmAb A with a PD-1 inhibitor as a frontline combination therapy in EGFR wild type non-small cell lung cancer was recently initiated. In the EGFR mutant segment, we plan to initiate studies for tmAb A as a monotherapy in the second line setting and in combination with Osimertinib in the first line setting. Preliminary Phase 1 results will be presented at the upcoming ASCO meeting. This year, Phase 2 data from our CRC study evaluating tmAb A in combination with Bevacizumab will be available, which could enable a Phase 3 study in an all comers population. Progress also continues with ABBV-706 in small cell lung cancer. Recall, this ADC utilizes the same topo warhead and linker technology as tmAb A, but with an antibody that targets SEZ6. In the Phase 1 study, 706 was efficacious across doses with an objective response rate of approximately 60% in patients with relapsed or refractory small cell lung cancer. Based on maturing duration of response and progression free survival data, we plan to advance 706 into a trial in a relapsed refractory population and a dose optimization study in combination with a PD-L1 in the frontline with the goal of establishing a chemo sparing regimen as a new standard of care. In the area of hematologic oncology, the data readout remains on track for the Phase 3 VENCLEXTA MDS trial. And if positive, our regulator”